Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Prevost

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 7, 2010
Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targetingZhiyong Poon, Jung Ah Lee, Shenwen Huang, et al.
Biotechnology and Bioengineering|April 1, 1999
High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vectorP J Farrell, M Lu, J Prevost, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|May 1, 1999
[Idiopathic thrombocytopenic purpura: long-term outcome]J J Choulot, A Dos Santos, J Prevost, et al.
Radiology|April 1, 1986
MR imaging of the acutely injured patient with cervical tractionC B McArdle, J W Wright, W J Prevost, et al.
Revue De Laryngologie - Otologie - Rhinologie|September 7, 2013
Development of an osteosarcoma following dental extraction after allogeneic stem cell transplantationB Phulpin, N Marchettic, L Mansuyd, et al.
Biochemistry|October 7, 1998
The soluble granulocyte-macrophage colony-stimulating factor receptor's carboxyl-terminal domain mediates retention of the soluble receptor on the cell surface through interaction with the granulocyte-macrophage colony-stimulating factor receptor beta-subunitE W Murray, C Pihl, S M Robbins, et al.
Presse Medicale (Paris, France : 1983)|October 13, 1998
[Improvement of prescriptions for serum tumor markers in a general hospital]A Pariente, J Prevost, N Montaut, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 7, 2010
Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targetingZhiyong Poon, Jung Ah Lee, Shenwen Huang, et al.
Biotechnology and Bioengineering|April 1, 1999
High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vectorP J Farrell, M Lu, J Prevost, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|May 1, 1999
[Idiopathic thrombocytopenic purpura: long-term outcome]J J Choulot, A Dos Santos, J Prevost, et al.
Radiology|April 1, 1986
MR imaging of the acutely injured patient with cervical tractionC B McArdle, J W Wright, W J Prevost, et al.
Revue De Laryngologie - Otologie - Rhinologie|September 7, 2013
Development of an osteosarcoma following dental extraction after allogeneic stem cell transplantationB Phulpin, N Marchettic, L Mansuyd, et al.
Biochemistry|October 7, 1998
The soluble granulocyte-macrophage colony-stimulating factor receptor's carboxyl-terminal domain mediates retention of the soluble receptor on the cell surface through interaction with the granulocyte-macrophage colony-stimulating factor receptor beta-subunitE W Murray, C Pihl, S M Robbins, et al.
Presse Medicale (Paris, France : 1983)|October 13, 1998
[Improvement of prescriptions for serum tumor markers in a general hospital]A Pariente, J Prevost, N Montaut, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 3